BUSINESS
36 Drug Makers Paid Approximately 400 Billion Yen to Doctors, Medical Institutions in FY2012; Mainly for R&D, But Also for Information
Drug makers have begun disclosing details of the money they paid to doctors and medical institutions in FY2012 based on the transparency guidelines drawn up by the Japan Pharmaceutical Manufacturers Association (JPMA). Disclosure commenced with Pfizer Japan, which announced its…
To read the full story
BUSINESS
- Bayer Detects Nitrosamine in Contrast Agent, Restricts Shipments
April 27, 2026
- Chugai to Launch 3 Global PIIIs of Bispecific Antibody NXT007 in 2026
April 27, 2026
- Astellas Bags US$75 Million from MSN after Myrbetriq Patent Settlement
April 27, 2026
- Kura, Kyowa Kirin Start Japan PII Trial of Ziftomenib for AML Filing
April 27, 2026
- Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





